NASDAQ: TSVT - 2seventy bio, Inc.

Yield per half year: +20.51%
Sector: Healthcare

Share chart 2seventy bio, Inc.


About

2seventy bio, Inc., компания, занимающаяся клеточной и генной терапией, специализируется на исследованиях, разработке и коммерциализации методов лечения рака в Соединенных Штатах. В ассортимент продукции компании входят idecabtagene vicleucel; ide-cel или Abecma и bb21217; и кандидаты на продукты CAR-T-клеток для лечения множественной миеломы. 2seventy bio, Inc. имеет соглашение о сотрудничестве с компанией Bristol-Myers Squibb. Компания была зарегистрирована в 2021 году, ее штаб-квартира находится в Кембридже, штат Массачусетс. 2seventy bio, Inc. (NasdaqGS: TSVT.

More details
V) работает независимо от bluebird bio, Inc. с 4 ноября 2021 года.


Main settings

Число акций ао 0.04928 млрд
P/S 12.06
EV/EBITDA -0.828
EBITDA -0.3226
Цена ао 5.15
Сайт https://www.2seventybio.com
P/BV 1.8274
Выручка 0.0443
Див.доход ао 0
ISIN US9013841070
Change price per day: -6.34% (5.52)
Change price per week: -3.18% (5.34)
Change price per month: +28.93% (4.01)
Change price per 3 month: +38.24% (3.74)
Change price per half year: +20.51% (4.29)
Change price per year: -41.71% (8.87)
Change price per year to date: +31.22% (3.94)


All parameters ⇨

Grade

Underestimation

Title Value Grade
P/S 12.06 7
P/BV 1.8274 9
P/E 0 0
EV/EBITDA -0.828 0
Total:

Efficiency

Title Value Grade
ROA, % -35.61 0
ROE, % -76.91 0
Total:

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total:

Debt

Title Value Grade
Debt/EBITDA -1.2437 10
Total:

Growth impulse

Title Value Grade
Profit growth, % 15.01 3
Share price growth, % 0 0
Dividend growth, % 0 0
Total:

Insider trading

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
25.03.2024 25.03.2024 Casdin Capital, LLC
Director
Buy 5.07 1 673 100 330000 0 1.41 link
22.03.2024 25.03.2024 Casdin Capital, LLC
Director
Buy 5.12 754 570 147377 0 0.63 link
21.03.2024 25.03.2024 Casdin Capital, LLC
Director
Buy 4.9 1 470 000 300000 0 1.28 link
10.08.2023 16.08.2023 Kynam Global Healthcare Master
10% Owner
Buy 5.92 3 051 250 515414 0 2.21 link
10.08.2023 16.08.2023 Kynam Global Healthcare Master
10% Owner
Buy 5.96 515 027 86414 0 0.37 link

Main owners

Institutions Volume Share, %
Kynam Capital Management, LP 5953825 11.6
Morgan Stanley 4842810 9.44
Goldman Sachs Group Inc 4508800 8.79
Vanguard Group Inc 3985770 7.77
Blackrock Inc. 3911724 7.62
Baker Brothers Advisors, LLC 2497526 4.87
Millennium Management LLC 2335272 4.55
Madison Avenue Partners, LP 1754788 3.42
Engine Capital Management, LP 1494304 2.91
DAFNA Capital Management, LLC 1447465 2.82

Contained in ETF

ETF Share, % Profitability for 1 year, % Dividends, %
Range Cancer Therapeutics ETF 1.67 20.43

Similar companies



Company management

Head Job title Payment Year of birth
Mr. Nick Leschly President & Director 1.81M 1973 (51 year)
Ms. Susan Abu-Absi Ph.D. Chief Technology Officer N/A
Dr. Philip D. Gregory D. Phil., DPHIL Chief Scientific Officer 1.01M 1971 (53 years)
Ms. Teresa L. Jurgensen J.D. Senior VP, General Counsel & Corporate Secretary N/A
Ms. Jenn Snyder Senior Vice President of Corporate Affairs N/A
Mr. William D. Baird III, M.B.A. Chief Executive Officer 810.83k 1972 (52 years)
Dr. Steven Bernstein M.D. Chief Medical Officer N/A
Ms. Kerri Jensen Head of People & Culture N/A
Vicki Eatwell Chief Financial Officer N/A
Jessica Snow Senior VP of Quality and Head of Operations N/A

About company

Address: United States, Cambridge. MA, 60 Binney Street - open in Google maps, open in Yandex maps
Website: https://www.2seventybio.com
Phone: +tel:3394999300